Q-omics provides the consensus-scored IGFBP6 profile across patient tissues and cancer cell-line models. IGFBP6 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IGFBP6 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, IGFBP6 protein abundance shows 21,583 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, BLCA, and GBM as cancer lineages where IGFBP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGFBP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGFBP6 survival associations across molecular data types. IGFBP6 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGFBP6 RNA expression–survival associations across cancer types. High IGFBP6 expression shows unfavorable associations in ACC, GBM, UCS and LUSC, but favorable associations in KIRP and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for IGFBP6 RNA expression.
This table summarizes IGFBP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IGFBP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGFBP6 shows lower tumor expression in BLCA, COAD, KICH and STAD and higher tumor expression in KIRP and THCA. The BLCA box plot shows higher IGFBP6 RNA expression in normal versus tumor tissue (log2 FC = −3.025, t-test p < 0.001).
This table shows molecular features associated with IGFBP6 in patient tissues and cancer cell lines. In patient samples, IGFBP6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGFBP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
